

## ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity<sup>☆</sup>

Tomoharu Takeuchi, Hideyoshi Yokosawa<sup>\*</sup>

*Department of Biochemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan*

Received 26 July 2005

Available online 15 August 2005

### Abstract

ISG15 is one of the interferon-stimulated genes and is classified as a ubiquitin-like protein. Upon interferon stimuli, ISG15 is upregulated and becomes conjugated to various cellular proteins (ISGylation). Several target proteins for ISGylation have recently been identified, but the biological consequence of protein ISGylation remains unclear. In the course of our study to identify components of the ISGylation system, we found that Ubc13, an E2 enzyme for ubiquitin conjugation, is covalently modified with ISG15. To determine the meaning of ISGylation of Ubc13, we isolated ISG15-modified Ubc13 protein and compared its ubiquitin-conjugating activity with that of an unmodified one. We found that ISGylation of Ubc13 suppresses its ability to form a thioester intermediate with ubiquitin.

© 2005 Elsevier Inc. All rights reserved.

**Keywords:** ISG15; Interferon; Ubiquitin; Ubiquitin-conjugating enzyme; Ubc13

ISG15 is one of the interferon-stimulated genes and it contains two ubiquitin-like domains [1–3]. Upon interferon stimuli, ISG15 is upregulated and becomes conjugated to diverse cellular proteins (ISGylation) [4]. It has been proposed that ISGylation is mediated by a sequential reaction similar to the ubiquitin conjugation system that consists of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase), and E1 and E2 enzymes but not E3 enzyme for ISGylation have been identified [5–7]. Recently, mice carrying null mutation of the gene for UBP43 (de-ISGylating enzyme) have been generated, and a series of analyses of the mice has suggested that protein ISGylation has an important role in innate immunity against viral infection [8–11]. To date, several target proteins for

ISGylation have been identified, but the biological consequence of protein ISGylation remains unclear [12,13].

Ubc13 is an exceptional E2 enzyme for ubiquitin conjugation because it forms a heterodimer with Mms2, an E2-like protein that lacks the catalytic Cys residue, and the Ubc13–Mms2 complex catalyzes the assembly of a K63-linked polyubiquitin chain [14–17]. Unlike the K48-linked polyubiquitin chain, a signal for proteasome-mediated protein degradation, the K63-linked polyubiquitin chain is not involved in proteasome-mediated degradation and functions in DNA repair and IκB kinase activation [18–21].

In this study, we found that Ubc13 is covalently modified with ISG15 and that ISGylation of Ubc13 suppresses its formation of a thioester intermediate with ubiquitin.

<sup>☆</sup> *Abbreviations:* ISG, interferon-stimulated gene; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; E3, ubiquitin ligase; IκB, inhibitor of nuclear factor-κB; PCR, polymerase chain reaction; DTT, dithiothreitol; GST, glutathione S-transferase.

<sup>\*</sup> Corresponding author. Fax: +81 11 706 4900.

E-mail address: [yoko@pharm.hokudai.ac.jp](mailto:yoko@pharm.hokudai.ac.jp) (H. Yokosawa).

### Materials and methods

*Cell culture and transfection.* A549 and HeLa cells were cultured in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10%

heat-inactivated fetal bovine serum (Invitrogen) and 10% heat-inactivated calf serum (Hyclone), respectively. Transfection in A549 cells was performed using Metafectene (Biontex) according to the manufacturer's protocol, while that in HeLa cells was performed according to the standard calcium precipitation protocol.

**Plasmid construction.** The open reading frames of human ISG15, UBE1L (an E1 for ISGylation), Ubc13 (UBE2N), and Mms2 (UBE2V2) were amplified by PCR. Point mutants of Ubc13 were generated by PCR. All constructs were verified by DNA sequencing. To generate the expression plasmids, the PCR fragments were subcloned into pCI-neo-6His, pCI-neo-3Flag, pCI-neo-3T7, and pCI-neo-2S vectors that had been generated by inserting oligonucleotides encoding a histidine tag sequence (6His), three repeats of a Flag tag sequence, three repeats of a T7 tag sequence, and two repeats of an S peptide sequence, respectively, into the pCI-neo mammalian expression vector (Promega).

**Immunoprecipitation and Western blotting.** A549 cells that had been transiently transfected with the indicated plasmids and cultured for 30 h were washed with ice-cold phosphate-buffered saline and lysed with RIPA buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, and 0.5% sodium deoxycholate. The cell lysate was sonicated for 3 s and the debris was removed by centrifugation. The resulting supernatant was incubated with anti-Flag M2 antibody-immobilized agarose (Sigma), and the immunoprecipitate was washed five times with RIPA buffer.

For Western blotting, the whole cell lysate and the immunoprecipitate were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were immunoblotted with anti-Flag tag M2 (Sigma), anti-T7 tag (Novagen), and anti-S peptide (Santa Cruz) antibodies and were subsequently incubated with horseradish peroxidase-conjugated antibodies against mouse or rabbit immunoglobulin (Amersham Biosciences), followed by detection with ECL immunoblotting detection reagents (Amersham Biosciences).

**Isolation of ISGylated and unmodified Ubc13 proteins.** To prepare ISGylated Ubc13 protein, HeLa cells were transiently transfected with the pCI-neo-3Flag-Ubc13, pCI-neo-2S-UBE1L, and pCI-neo-6His-ISG15 plasmids and cultured for 48 h. The cells were washed with ice-cold phosphate-buffered saline and were then lysed with phosphate-buffered saline containing 0.2% Nonidet P-40 and 1 mM DTT. The cell lysate was sonicated for 3 s and the debris was removed by centrifugation. The resulting supernatant was incubated with Talon resin (BD Biosciences) and the resins were extensively washed with phosphate-buffered saline containing 0.2% Nonidet P-40. The materials bound to the resins were eluted with 300 mM imidazole. The eluted ISGylated proteins were diluted with phosphate-buffered saline containing 0.2% Nonidet P-40, and 1 mM DTT and were then incubated with anti-Flag M2 antibody-immobilized agarose beads. The resulting immunoprecipitate was extensively washed with phosphate-buffered saline containing 0.2% Nonidet P-40, followed by washing three times with a buffer containing 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.2% Nonidet P-40, and 10% glycerol. The materials bound to the beads were eluted with 3× Flag peptide (200 µg/ml) and used as ISGylated Ubc13 that had been Flag-tagged. On the other hand, to prepare unmodified Ubc13 protein, HeLa cells were transiently transfected only with the pCI-neo-3Flag-Ubc13 plasmid, and the lysate was prepared as described above. The cell lysate was sonicated for 3 s and the debris was removed by centrifugation. The resulting supernatant was incubated with anti-Flag M2 antibody-immobilized agarose beads and Flag-tagged Ubc13 was eluted as described above.

**In vitro ubiquitination and binding assays.** GST-ubiquitin and Uba1 (an E1 for ubiquitination) were prepared as described previously [22]. To analyze in vitro formation of the Ubc13-ubiquitin thioester intermediate, 2 µg GST-ubiquitin, 200 ng Uba1, and 2 ng ISGylated or unmodified Ubc13 that had been Flag-tagged were incubated in a reaction mixture (20 µl) containing 25 mM Tris-HCl, pH 7.6, 50 mM NaCl, 10 mM MgCl<sub>2</sub>, 5 mM ATP, 0.1 mM DTT, and 0.2 U of inorganic pyrophosphatase. The reaction was stopped by adding SDS-

PAGE loading buffer without DTT, and the reaction mixture was subjected to Western blotting with anti-Flag tag antibody.

To investigate the effect of ISGylation of Ubc13 on its binding with Mms2, we first prepared S-tagged Mms2 bound to S protein-immobilized agarose beads. HeLa cells were transiently transfected with the pCI-neo-2S-Mms2 plasmid and cultured for 36 h. The cells were washed with ice-cold phosphate-buffered saline and were then lysed with a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% Nonidet P-40, and 10% glycerol. The cell lysate was sonicated for 3 s and the debris was removed by centrifugation. The resulting supernatant was incubated with S protein-immobilized agarose beads (Novagen). The beads were extensively washed with a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% Nonidet P-40, and 10% glycerol, followed by washing three times with the same buffer, except for 500 mM NaCl. Next, the thus-prepared S-tagged Mms2 bound to the beads was incubated with the isolated ISGylated or unmodified Ubc13 in a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% Nonidet P-40, and 10% glycerol. After the beads had been extensively washed with the same buffer, the materials bound to the beads were subjected to Western blot analysis as described above.

## Results and discussion

### *Ubc13 is covalently modified with ISG15*

In the course of our study to identify components of the ISG15 conjugation system and its target proteins, we identified Ubc13, an E2 enzyme for the ubiquitin conjugation system, as a candidate target protein for ISG15 conjugation. We expressed Flag-tagged Ubc13 together with T7-tagged ISG15 and S-tagged UBE1L (the E1 for the ISG15 conjugation system) in A549 cells, and the extract of transfected cells was subjected to Western blotting with anti-Flag tag antibody (Fig. 1A). In the case of co-expression of Ubc13 with both ISG15 and UBE1L, one band with slower mobility (Fig. 1A, open arrowhead) than that of the intact one (closed arrowhead) was detected. On the other hand, when we expressed Ubc13 only, the corresponding band with slower mobility was not detected. These results suggest that Ubc13 is covalently modified with ISG15. To obtain definitive evidence for this, we next carried out immunoprecipitation experiments. The above extract of transfected cells was subjected to immunoprecipitation with anti-Flag tag antibody in a buffer containing 0.1% SDS, followed by Western blotting with anti-T7 tag antibody (Fig. 1B). Ubc13 was again found to be modified with ISG15 in the case of co-expression of Ubc13 with both ISG15 and UBE1L (Fig. 1B, open arrowhead). These results indicate that Ubc13 is covalently modified with ISG15 in A549 cells.

### *Ubc13 is modified with ISG15 through Lys92*

To study the biological consequence of ISG15 conjugation to Ubc13, it is important to determine the Lys




Fig. 1. Ubc13 is covalently modified with ISG15. (A) The extract of A549 cells that had expressed Flag-tagged Ubc13 together with T7-tagged ISG15 and S-tagged UBE1L as indicated was subjected to Western blotting with anti-Flag tag antibody. (B) The extract of A549 cells that had expressed Flag-tagged Ubc13 together with T7-tagged ISG15 and S-tagged UBE1L as indicated was subjected to immunoprecipitation (IP) with anti-Flag tag antibody. The resulting immunoprecipitates were subjected to Western blotting with anti-T7 tag antibody. ISG15-modified Ubc13 (T7-ISG15-Flag-Ubc13) is indicated by an open arrowhead, and the original Flag-tagged Ubc13 in (A) and free T7-tagged ISG15 in (B) are indicated by closed arrowheads. Non-specific bands are indicated by asterisks.

residue in Ubc13 that is covalently modified with ISG15. As Ubc13 contains a few Lys residues near the catalytic Cys87 residue, we assumed that ISG15 conjugation to Ubc13 through a Lys residue located adjacent to the active site could affect the activity of Ubc13. To test this assumption, we constructed two Ubc13 K92R and K94R mutants, in which the Lys92 and Lys94 residues had been changed to Arg. We expressed the Flag-tagged Ubc13 mutant together with T7-tagged ISG15 and S-tagged UBE1L in A549 cells, and the extract of transfected cells was subjected to Western blotting with anti-Flag tag antibody (Fig. 2). In contrast to the cases of the wild-type and K94R mutant, we failed to detect a band that corresponded to ISG15-modified Ubc13 in the case of the K92R mutant. Thus, we concluded that Ubc13 is modified with ISG15 at least through Lys92.




Fig. 2. Ubc13 is covalently modified with ISG15 through Lys92. The extract of A549 cells that had expressed either Flag-tagged wild-type Ubc13 or its mutant (K92R or K94R) in which the Lys residue had been changed to Arg together with T7-tagged ISG15 and S-tagged UBE1L was subjected to Western blotting with anti-Flag tag antibody. ISG15-modified Ubc13 (T7-ISG15-Flag-Ubc13) is indicated by an open arrowhead, and the original Flag-tagged Ubc13 or its mutant is indicated by a closed arrowhead.

### ISG15 modification of Ubc13 suppresses its formation of thioester intermediate with ubiquitin

The above-described finding that Ubc13 is modified with ISG15 through Lys92 near the catalytic Cys residue led us to speculate that the modification of Ubc13 by ISG15 could antagonize its formation of the thioester intermediate with ubiquitin: this speculation seemed to be reasonable on the basis of the structural information concerning Ubc13 [16,17]. To confirm this possibility, we isolated ISGylated and unmodified Ubc13 proteins, and we analyzed their abilities to form thioester intermediates with ubiquitin. The isolated ISGylated or unmodified Ubc13 was incubated with both GST-ubiquitin and Uba1 (yeast E1 for ubiquitin conjugation) to allow formation of the Ubc13-ubiquitin thioester intermediate. The reaction mixture was then subjected to Western blotting with anti-Flag tag antibody under non-reducing conditions (Fig. 3A). In the case of unmodified Ubc13, one band with slower mobility (Fig. 3A, lane 4, open arrowhead) than that of unmodified Ubc13 (Fig. 3A, closed arrowhead), which corresponded to the Ubc13-ubiquitin thioester intermediate, was detected in the presence of GST-ubiquitin and E1. On the other hand, in the case of ISG15-modified Ubc13, a band corresponding to the ISGylated Ubc13-ubiquitin thioester intermediate was not detected under the same conditions. The band in the former case detected under non-reducing conditions was not detected under reducing conditions (data not shown). To confirm the above results, we analyzed time dependence of the formation of the Ubc13-ubiquitin thioester intermediate in either case (Fig. 3B). The band corresponding to the ubiquitin thioester intermediate increased in a time-dependent manner in the case of unmodified Ubc13 (Fig. 3B, lanes 1–5, open arrowhead), while the band corresponding to the ISGylated Ubc13-ubiquitin thioester intermediate was not detected again even when the incubation time




Fig. 3. ISGylation of Ubc13 suppresses its formation of the thioester intermediate with ubiquitin. (A,B) GST-ubiquitin (GST-Ub), Uba1 (E1), and either unmodified Ubc13 (Flag-Ubc13 (E2), lanes 1–5) or ISG15-modified Ubc13 (ISG15-Flag-Ubc13 (E2), lanes 6–10) were incubated at 30 °C for 60 min (A) or for various times (B) and were then subjected to Western blotting with anti-Flag tag antibody under non-reducing conditions. The original unmodified (lanes 1–5) and ISGylated Ubc13 (lanes 6–10) are indicated by a closed arrowhead and an arrow, respectively. The ubiquitin thioester intermediate in the case of unmodified Ubc13 is indicated by an open arrowhead. (C) Isolated unmodified Ubc13 (Flag-Ubc13) or ISGylated Ubc13 (ISG15-Flag-Ubc13), both of which had been Flag-tagged, was pulled down with S-tagged Mms2 bound to S protein-immobilized agarose beads or control S protein-immobilized agarose beads. The materials bound to the beads were subjected to Western blotting with anti-Flag tag and anti-S peptide antibodies.

was prolonged (Fig. 3B, lanes 6–10). It should be noted that the isolated ISG15-modified and unmodified Ubc13 preparations contained ubiquitin-modified ones, because a band with slower mobility than that due to the original one was detected in either case in Figs. 3A and B. In these experiments, we used ISG15-modified and unmodified Ubc13 isolated from the transfected cells. Although an E3 enzyme for ISG15 conjugation has not been identified, the construction of an *in vitro* ISG15 conjugation system is necessary to obtain pure ISG15-modified and unmodified Ubc13 proteins.

Since Ubc13 forms a heterodimer with Mms2, we next determined whether ISGylation of Ubc13 has an influence on its binding with Mms2. We first prepared S-tagged Mms2 bound to S protein-immobilized agarose beads. The thus-prepared beads were incubated with ISG15-modified or unmodified Ubc13, and the materials bound to the beads were then subjected to Western blotting with anti-Flag tag and anti-S peptide antibodies (Fig. 3C). ISGylation of Ubc13 had little effect on the binding ability of Ubc13 with Mms2. These results strongly suggest that ISG15-modified Ubc13 is capable of forming a heterodimer with Mms2 but is unable to form the thioester intermediate with ubiquitin.

In the present study, we found that Ubc13 is covalently modified with ISG15 and that ISGylation of Ubc13 suppresses its formation of the thioester intermediate with ubiquitin. Recently, independently of

our study, Ubc13 has been proposed to be a candidate target of ISGylation on the basis of results obtained by using a proteomics approach [23]. Our results presented here agree with this proposal and, furthermore, provide evidence for the biological consequence of ISGylation of Ubc13 and a link between the ubiquitin conjugation system and the ISG15 conjugation system. In mammalian cells, the K63-linked polyubiquitin chain, formed by the Ubc13–Mms2 complex, is known to play a key role in activation of the I $\kappa$ B kinase complex by signal transduction through Toll-like receptors, tumor necrosis factor receptor, B-cell receptor, and T-cell receptor [20,21,24,25]. Our results showing that Ubc13 is covalently modified with ISG15, resulting in the suppression of its activity, imply ISG15 conjugation-dependent inhibition of K63-linked polyubiquitin chain formation, leading to the inhibition of nuclear factor- $\kappa$ B activity. Such lines of study are now under way to identify the biological consequence of ISG15 modification of Ubc13 under physiological conditions.

#### Acknowledgments

This study was supported in part by Grants-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

## References

- [1] D.C. Schwartz, M. Hochstrasser, A superfamily of protein tags: ubiquitin, SUMO and related modifiers, *Trends Biochem. Sci.* 28 (2003) 321–328.
- [2] K.I. Kim, D.E. Zhang, ISG15, not just another ubiquitin-like protein, *Biochem. Biophys. Res. Commun.* 307 (2003) 431–434.
- [3] K.J. Ritchie, D.E. Zhang, ISG15: the immunological kin of ubiquitin, *Semin. Cell Dev. Biol.* 15 (2004) 237–246.
- [4] K.R. Loeb, A.L. Haas, The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins, *J. Biol. Chem.* 267 (1992) 7806–7813.
- [5] W. Yuan, R.M. Krug, Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein, *EMBO J.* 20 (2001) 362–371.
- [6] C. Zhao, S.L. Beaudenon, M.L. Kelley, M.B. Waddell, W. Yuan, B.A. Schulman, J.M. Huibregtse, R.M. Krug, The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN- $\alpha/\beta$ -induced ubiquitin-like protein, *Proc. Natl. Acad. Sci. USA* 101 (2004) 7578–7582.
- [7] K.I. Kim, N.V. Giannakopoulos, H.W. Virgin, D.E. Zhang, Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation, *Mol. Cell. Biol.* 24 (2004) 9592–9600.
- [8] M.P. Malakhov, O.A. Malakhova, K.I. Kim, K.J. Ritchie, D.E. Zhang, UBP43 (USP18) specifically removes ISG15 from conjugated proteins, *J. Biol. Chem.* 277 (2002) 9976–9981.
- [9] O.A. Malakhova, M. Yan, M.P. Malakhov, Y. Yuan, K.J. Ritchie, K.I. Kim, L.F. Peterson, K. Shuai, D.E. Zhang, Protein ISGylation modulates the JAK-STAT signaling pathway, *Genes Dev.* 17 (2003) 455–460.
- [10] K.J. Ritchie, M.P. Malakhov, C.J. Hetherington, L. Zhou, M.T. Little, O.A. Malakhova, J.C. Sipe, S.H. Orkin, D.E. Zhang, Dysregulation of protein modification by ISG15 results in brain cell injury, *Genes Dev.* 16 (2002) 2207–2212.
- [11] K.J. Ritchie, C.S. Hahn, K.I. Kim, M. Yan, D. Rosario, L. Li, J.C. de la Torre, D.E. Zhang, Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection, *Nat. Med.* 10 (2004) 1374–1378.
- [12] J.A. Hamerman, F. Hayashi, L.A. Schroeder, S.P. Gygi, A.L. Haas, L. Hampson, P. Coughlin, R. Aebersold, A. Adrem, Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog, *J. Immunol.* 168 (2002) 2415–2423.
- [13] M.P. Malakhov, K.I. Kim, O.A. Malakhova, B.S. Jacobs, E.C. Borden, D.E. Zhang, High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction, *J. Biol. Chem.* 278 (2003) 16608–16613.
- [14] R.M. Hofmann, C.M. Pickart, Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair, *Cell* 96 (1999) 645–653.
- [15] R.M. Hofmann, C.M. Pickart, In vitro assembly and recognition of Lys-63 polyubiquitin chains, *J. Biol. Chem.* 276 (2001) 27936–27943.
- [16] A.P. VanDemark, R.M. Hofmann, C. Tsui, C.M. Pickart, C. Wolberger, Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer, *Cell* 105 (2001) 711–720.
- [17] T.F. Moraes, R.A. Edwards, S. McKenna, L. Pastushok, W. Xiao, J.N. Glover, M.J. Ellison, Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2–hUbc13, *Nat. Struct. Biol.* 8 (2001) 669–673.
- [18] L. Sun, Z.J. Chen, The novel functions of ubiquitination in signaling, *Curr. Opin. Cell Biol.* 16 (2004) 119–126.
- [19] C. Hoege, B. Pfander, G.L. Moldovan, G. Pyrowolakis, S. Jentsch, RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO, *Nature* 419 (2002) 135–141.
- [20] L. Deng, C. Wang, E. Spencer, L. Yang, A. Braun, J. You, C. Slaughter, C. Pickart, Z.J. Chen, Activation of the I $\kappa$ B kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain, *Cell* 103 (2000) 351–361.
- [21] A. Kanayama, R.B. Seth, L. Sun, C.K. Ea, M. Hong, A. Shaito, Y.H. Chiu, L. Deng, Z.J. Chen, TAB2 and TAB3 activate the NF- $\kappa$ B pathway through binding to polyubiquitin chains, *Mol. Cell* 15 (2004) 535–548.
- [22] Y. Saeki, Y. Tayama, A. Toh-e, H. Yokosawa, Definitive evidence for Ufd2-catalyzed elongation of the ubiquitin chain through Lys48 linkage, *Biochem. Biophys. Res. Commun.* 320 (2004) 840–845.
- [23] C. Zhao, C. Denison, J.M. Huibregtse, S. Gygi, R.M. Krug, Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways, *Proc. Natl. Acad. Sci. USA* 102 (2005) 10200–10205.
- [24] L. Sun, L. Deng, C.K. Ea, Z.P. Xia, Z.J. Chen, The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes, *Mol. Cell* 14 (2004) 289–301.
- [25] H. Zhou, I. Wertz, K. O'Rourke, M. Ultsch, S. Seshagiri, M. Eby, W. Xiao, V.M. Dixit, Bcl10 activates the NF- $\kappa$ B pathway through ubiquitination of NEMO, *Nature* 427 (2004) 167–171.